SLU7 and myelodysplastic syndrome: Emerging evidence from our study on SF3B1 and the study on U2AF145 thus supports the hypothesis that in MDS patients harboring splicing factor mutations, there is widespread disruption of the splicing machinery as a consequence of downstream effects of the mutant protein.